

ESTEVE increases its production capacity in Spain

- **Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona**
- **The new plant covers more than 21,000 m², has a team of 89 people and a production capacity of 160 m³ of reaction volume**

Barcelona, 1 February 2022 - The pharmaceutical group ESTEVE has signed, through Esteve Química, an agreement to purchase the fine chemicals industrial facility run to date by UQUIFA in LLiçà de Vall (Barcelona).

The purchase of this facility, which is fully in line with ESTEVE's expansion strategy, will increase its capacity to manufacture active ingredients and expand its product portfolio and production capacity and thereby securing the group's continued growth.

The LLiçà de Vall site occupies a surface area of 21,176 m², a workforce of 89 people and a production capacity of 160 m³ of reaction volume (added to the total of 875 m³) It currently produces advanced intermediates and active pharmaceutical ingredients, which are exported to Europe, the United States, Latin America and Asia.

This facility meets Good Manufacturing Practices (GMPs) and have the corresponding AEMPS (Spanish Health Agency) certification, as well as ISO14001:2005 certification covering environmental aspects. They are also audited by several international regulatory authorities such as the Korean FDA and the Japanese PMDA.

Staffan Schüberg, CEO of ESTEVE, commented: "This operation is an excellent opportunity to increase our industrial capacity and serve our customers and patients worldwide, to improve people's health and be true to our purpose. We are advancing towards our vision of becoming an international proprietary specialty pharma and with this opportunity we will be able to expand our services to the global specialty pharma market".

Celebrating this landmark event, Pere Mañé, Chief Industrial Operations Officer, said: "This acquisition fits our strategy perfectly and pushes two of our main levers, internationalization and growth. This new center allows us to substantially increase our technological and production capacity and to continue positioning Esteve Química as an international reference partner for the development and manufacture of active pharmaceuticals ingredients for specialty pharma companies around the world".

Saurabh Gurnurkar, Managing Director of UQUIFA Sciences, said: "The UQUIFA team is pleased that the LLiçà de Vall site will get a committed owner with the capacity to develop it to its full potential. This divestment will help UQUIFA streamline our Spanish operations in line with our strategic goals and better align with our customers' evolving needs".

About ESTEVE

ESTEVE (www.esteve.com) is a global pharmaceutical company with headquarters in Barcelona. Its mission is to advance in innovation to improve people's lives and, since it was founded in 1929, its focus has been to provide solutions for as yet unmet medical needs. ESTEVE has an important presence in Europe thanks to its affiliates in Spain, Germany, France and UK and its own production centers dedicated to the development and manufacture of active pharmaceutical ingredients in Spain, Mexico and China, as well as a pharmaceutical plant in Germany.

About UQUIFA

The UQUIFA Group (www.uquifa.com) is a Barcelona headquartered small-molecule API (active pharmaceutical ingredient) development and manufacturing enterprise. Founded in 1936, the UQUIFA Group today, caters to a global customer base from its sites in Spain, Mexico and Hungary across the CDMO and Off-Patent API business lines. It is focused on delivering value through its development & manufacturing capabilities to a customer base across the pharmaceutical and specialty chemical industries with the USA, EU and Japan being its principal markets.

For more information

Olga Cajal, ESTEVE Communications, Tel. 93 446 62 60, ocajal@esteve.com